Want to see CBIO full AI Analyst Report?
CBIO Stock Chart & Stats
$17.76
$0.94(5.77%)
At close: 4:00 PM EDT
$17.76
$0.94(5.77%)
Day’s Range― - ―
52-Week Range$8.72 - $27.41
Previous CloseN/A
Volume130.39K
Average Volume (3M)229.91K
Market Cap
$688.65M
Enterprise Value$383.42
Total Cash (Recent Filing)$171.59M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 05, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding37,143,940
10 Day Avg. Volume231,394
30 Day Avg. Volume229,906
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.61
Price to Sales (P/S)11.39
P/FCF Ratio-0.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.50Price Target Upside66.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.71
Revenue Forecast (FY)$1.86M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces interest obligations and refinancing exposure, giving Crescent Biopharma greater financial flexibility than a highly leveraged biotech. This buffer could help preserve strategic options while the company works to scale its operations.
Modest Revenue GrowthRevenue is still small, but the increase indicates some expansion in the company’s commercial or partnered activity. Sustained growth could gradually improve operating leverage if revenue scales faster than the substantial expense base.
Governance ContinuityShareholder support for the board and auditor provides continuity in oversight and financial reporting. Annual say-on-pay votes also create a recurring accountability mechanism that may improve alignment between management and investors.
Bears Say
Severe Operating LossesLosses remain extremely large relative to revenue, showing that the current business lacks operating leverage and is not near self-sustaining economics. Persistent expense intensity could require restructuring, asset prioritization, or continued external financing.
Heavy And Worsening Cash BurnSubstantial negative operating and free cash flow indicates ongoing dependence on cash reserves or capital markets. The deterioration from 2025 increases liquidity risk and may constrain research investment or force financing on unfavorable terms.
Eroding Equity BaseDeclining equity is consistent with sustained losses and potentially dilutive financing effects, weakening the company’s capital cushion. If losses continue, further equity erosion could reduce financial resilience and increase dependence on new funding.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $27.41 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $688.65M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.736 by -$0.004.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate is -0.67.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 37,143,940 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.736. Following the earnings report the stock price went up 1.693%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (66.10% Upside)
$29.50 (66.10% Upside)
Hedge Fund Trend
Increased
By 83.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crescent Biopharma
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$29.50
▲(66.10% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―
Ownership Overview
11.26% Insiders
5.25% Mutual Funds
48.04% Other Institutional Investors
29.67% Public Companies and
Individual Investors